Attention Deficit Hyperactivity Disorder (ADHD) News and Research

RSS

Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral).

Help Group Summit 2009 on autism, learning disabilities and ADHD

The Help Group Summit 2009 - Advances and Best Practices in Autism, Learning Disabilities and ADHD took place on Friday, October 2nd and Saturday, October 3rd at The Skirball Cultural Center in Los Angeles. This cutting edge conference featured more than 20 leading experts from across the country.

7 Oct 2009

Liquorice consumption linked to shorter pregnancies and adverse affect on child's intelligence and behaviour

Expectant mothers who eat excessive quantities of liquorice during pregnancy could adversely affect their child's intelligence and behaviour, a study has shown.

7 Oct 2009

sNDA for Clonicel submitted to the FDA

Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

2 Oct 2009

Addrenex submits a sNDA to the FDA for Clonicel

Sciele Pharma, Inc., a Shionogi company, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

1 Oct 2009

Researchers stress the importance of ensuring quality psychiatric treatment in general practice settings

Fifty-nine percent of all prescriptions filled for psychotropic medications are written by general practitioners, according to a research report published this month in Psychiatric Services.

1 Oct 2009

Pfeiffer Treatment Center opens new Alzheimer’s care center in Illinois

Pfeiffer Treatment Center proudly announces that it has opened the Pfeiffer Center for Alzheimer’s care in Illinois.

1 Oct 2009

Pharmacological study for ADHD treatment amongst college students

In an effort to help one of the most under studied groups of sufferers of attention deficit hyperactivity disorder (ADHD), researchers at University of Rhode Island and Lehigh University have kicked off the first-ever controlled pharmacological study for treatment of ADHD amongst college students.

24 Sep 2009

KemPharm announces nomination of its second pipeline candidate

KemPharm, Inc. today announced the nomination of its second pipeline candidate, KP201, based on its proprietary ligand activated therapy (LAT) platform. KP201 is a new chemical entity (NCE) for the treatment of pain with the possibility of reduced abuse potential. KP201 joins lead candidate KP106, which is a novel prodrug candidate in development for ADHD.

16 Sep 2009

Legislation grants improve research and employment initiatives in Indiana University medical campus

Indiana University School of Medicine scientists have received more than $12 million in grants funded by the federal economic stimulus legislation, funding that has bolstered both research initiatives and research employment on the medical center campus.

16 Sep 2009

Transcendental Meditation aids students diagnosed with ADHD

A panel of physicians and scientists will report on the benefits of a simple meditation practice for aiding students diagnosed with ADHD during a national medical webinar, which will be hosted by the David Lynch Foundation on Wednesday, September 30, 12 noon (ET).

16 Sep 2009

Identification of genetic risk factors may lead to new treatments for ADHD

The majority of patients affected by ADHD in childhood carry ADHD symptoms, or even the full ADHD-diagnosis, into adulthood.

15 Sep 2009

CHADD survey reveals the importance of early diagnosis in treating Attention-Deficit/Hyperactivity Disorder

The results from an informal survey on AD/HD released today reinforce existing scientific research that the disorder does not affect children alone, and when left undiagnosed until adulthood, can create much larger relationship challenges for those with the disorder.

15 Sep 2009

Monoamine oxidases responsible for personality and behaviour

Antisocial and aggressive behaviours represent a widespread and expensive social problem. Recent research has convincingly shown that there is a strong interaction between genetic inheritance and environment for development of personality and behaviour.

14 Sep 2009

Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today confirmed plans to present data from its completed Phase 2b clinical trial of TC-5214 as an augmentation treatment for major depressive disorder at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium (nAChR2009) in Lincolnshire, Illinois on October 15, 2009.

10 Sep 2009

Half of six million major depressive disorder with comorbid panic attack cases go untreated

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in the U.S., out of six million cases of major depressive disorder with comorbid panic attack, three million are untreated. Comorbid mental disorders are influential factors impacting the diagnosis and treatment of mental disorders.

10 Sep 2009

Season's Practice launches women health and wellness solutions in Northeast Ohio

Season's Practice has opened its doors to women in Northeast Ohio who are seeking alternative health and wellness solutions to improve their overall health and well-being.

10 Sep 2009

Shire receives FDA approval for INTUNIV extended release tablets

Shire plc, the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.

4 Sep 2009

Shire's INTUNIV (Guanfacine) approved by the FDA for treatment of Attention-Deficit/Hyperactivity Disorder

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.

4 Sep 2009

LearningRx teaches parents on how to improve their kids' attention

September is National Attention Deficit Hyperactivity Disorder (ADHD) Awareness Month. And, more than 60 LearningRx franchisees are showing parents how to increase the three types of attention skills.

4 Sep 2009

CDC recommends routine health examintion for all school-age children

Although school has just begun, it is already exam time for students throughout Wisconsin. That's because in addition to notebook paper and pens, back-to-school preparations should also include routine health exams to make sure students are healthy and ready to learn. These include: a doctor's exam to confirm that all immunizations are up-to-date, a dental exam and a vision exam.

3 Sep 2009